You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Boehringer Ingelheim
Medtronic
Moodys
AstraZeneca

Last Updated: February 19, 2020

DrugPatentWatch Database Preview

Patent: 7,915,263

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,915,263
Title:Aminopyridine derivatives having aurora A selective inhibitory action
Abstract: The present invention relates to a compound of formula I: ##STR00001## wherein: R.sub.1 is a hydrogen atom, F, CN, etc.; R.sub.1\' is a hydrogen atom or lower alkyl which may be substituted; R.sub.2 is O, S, SO, SO.sub.2, etc.; R.sub.3 is a phenyl which may be substituted; X.sub.1, X.sub.2, and X.sub.3 each independently CH, N, etc. provided, however, that among X.sub.1, X.sub.2 and X.sub.3, the number of nitrogen is 0 or 1; W is the following residue: ##STR00002## wherein: W.sub.1, W.sub.2, and W.sub.3 each independently CH, N, etc., or a pharmaceutically acceptable salt or ester thereof.
Inventor(s): Iwasawa; Yoshikazu (Tsukuba, JP), Kato; Tetsuya (Tsukuba, JP), Kawanishi; Nobuhiko (Moriya, JP), Masutani; Kouta (Tsukuba, JP), Mita; Takashi (Tsukuba, JP), Nonoshita; Katsumasa (Tsukuba, JP), Ohkubo; Mitsuru (Ushiku, JP)
Assignee: Banyu Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:11/897,272
Patent Claims:see list of patent claims

Details for Patent 7,915,263

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX search
Eisai Inc ONTAK denileukin diftitox VIAL 103767 001 1999-02-05   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Start Trial Banyu Pharmaceutical Co., Ltd. (Tokyo, JP) 2026-08-31 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Mallinckrodt
Dow
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.